Ads
related to: rituximab for itp patient information sheet
Search results
Results From The WOW.Com Content Network
In general, patients with acute ITP will only rarely have life-threatening bleeding. [54] Most patients ultimately have lower, but stable platelet counts, which are still hemostatic for the patient. Unlike children and adolescents, ITP is often chronic in adults, even after a splenectomy. [40]
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that results in blood clots forming in small blood vessels throughout the body. [2] This results in a low platelet count, low red blood cells due to their breakdown, and often kidney, heart, and brain dysfunction. [1]
Rh o (D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. [2] It is often given both during and following pregnancy. [2] It may also be used when RhD-negative people are given RhD-positive blood. [2]
The experiment was undertaken in 1950 by William J. Harrington and James W. Hollingsworth, who postulated that in patients with idiopathic thrombocytopenic purpura (ITP), it was a blood factor that caused the destruction of platelets. [2] To test this hypothesis, Harrington received 500 ml of blood from a patient with ITP. [2]
Anti-platelet autoantibodies in a pregnant woman with immune thrombocytopenic purpura will attack the patient's own platelets and will also cross the placenta and react against fetal platelets. Therefore, ITP is a significant cause of fetal and neonatal immune thrombocytopenia.
Ad
related to: rituximab for itp patient information sheet